Genmab — Juni 2018
-
BCMAxCD3 (JNJ-957) https://twitter.com/MM_Hub/status/1008277611238363136 https://learningcenter.ehaweb.org/eha/2018/stockholm/214621/kristine.frerichs.preclinical.evaluation.of.the.new.bcmaxcd3.bispecific.html?f=media=3*speaker=663389 https://clinicaltrials.gov/ct2/show/NCT03145181 http://www.genmab.com/product-pipeline/products-in-development/jnj-64007957#tab1
-
Spændende uge vi går i møde. Handelskrigen ulmer. Recepttallene kommer på onsdag. Håber ikke fredagens relativt store fald, er pga forhåndsvi
den om skuffende recepttal. -
Selvom det burde være non event, har vi flere gange set det sagtens kan påvirke kursen. Desværre oftest i negativ retning.
-
Der også grænser for meget vi kan supplere. Vi tænkte jo allerede i kurs 1200, at den var billig. Derefter 1100 også 1000. Nu er den i 960.
-
Jeg er stadig 50% kontant, så har penge at gære godt med. Har dog allerede 500 Genmab aktier, så ved ikke om det ville være fornuftigt at købe flere. Fylder pænt i porten.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
yes, some RA news would be wonderfull…